Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 4/2021

01.12.2021 | editorial

Rare lung cancers—2021 update on challenges, advances, and opportunities

verfasst von: Dr. Andreas Pircher

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten
share
TEILEN

Excerpt

In the diagnostic and treatment landscape of various types of lung cancer, rare tumors represent a major challenge for patient management in terms of their biology, classification, and clinical behavior. In this scenario, the term rare lung cancer refers to a multitude of heterogeneous diseases including primary pulmonary sarcoma (PPS), neuroendocrine neoplasms (NEN) of the lung, thymic epithelial tumors (TET), malignant pleural mesothelioma (MPM), and other tumors often characterized by diagnostic pitfalls, the unavailability of prognostic and predictive biomarkers, and the lack of standardized treatments. In this issue, we compiled articles on the above-mentioned rare disease and tried to elaborate clinical dilemmas and to shed some light on diagnostics, treatment, and clinical management of rare lung cancers. …

Sie möchten Zugang zu diesem Inhalt erhalten? Dann informieren Sie sich jetzt über unsere Produkte:

Abo für kostenpflichtige Inhalte

Literatur
Metadaten
Titel
Rare lung cancers—2021 update on challenges, advances, and opportunities
verfasst von
Dr. Andreas Pircher
Publikationsdatum
01.12.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 4/2021
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00761-x